Caris Life Sciences, Inc.
NASDAQCaris Life Sciences is the biotech story of the week, with shares up 34% in five sessions and 80% over the past month — yet the short-selling and options data tell a story of measured repositioning rather than a forced squeeze. The context matters here. On August 5, CAI reported earnings that sent the stock up 24% in a single session, with a further 38% gain over the following five…
CAI short interest surges 25.7% in one week to 5.0% of float, driven by rising bearish sentiment on precision diagnostics headwinds.
Snapshot as of 10 Oct 2026
Caris Life Sciences is the biotech story of the week, with shares up 34% in five sessions and 80% over the past month — yet the short-selling and options data tell a story of measured repositioning rather than a forced…
Caris Life Sciences heads into Thursday's earnings print with one strikingly unusual signal: options traders have turned their most bullish in months, even as the stock has been in freefall. The clearest anomaly is the…
Caris Life Sciences delivered a Q1 revenue beat and reaffirmed full-year guidance, then watched its stock collapse anyway — down 19% the day after results and 13% on the week to $16.15. The gap between the reported…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CAI — free to start on ORTEX.
Sign up for free →Open CAI on ORTEX